{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:02:04Z","timestamp":1789650124953,"version":"4.0.0"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41571-026-01164-9","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:35:17Z","timestamp":1781688917000},"page":"672-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugates in gynaecological cancers: opportunities and challenges"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-1647","authenticated-orcid":false,"given":"Oladapo O.","family":"Yeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0309-6680","authenticated-orcid":false,"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1673-8384","authenticated-orcid":false,"given":"Hagop","family":"Youssoufian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1164_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"1164_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers. Mol. Cancer 23, 62 (2024).","journal-title":"Mol. Cancer"},{"key":"1164_CR3","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu, J. F. et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann. Oncol. 27, 2124\u20132130 (2016).","journal-title":"Ann. Oncol."},{"key":"1164_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan, R. et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J. Clin. Oncol. 38, 1824\u20131835 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJM198310133091503","volume":"309","author":"RC Bast Jr.","year":"1983","unstructured":"Bast, R. C. Jr. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883\u2013887 (1983).","journal-title":"N. Engl. J. Med."},{"key":"1164_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","volume":"27","author":"NG Ord\u00f3\u00f1ez","year":"2003","unstructured":"Ord\u00f3\u00f1ez, N. G. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 27, 1418\u20131428 (2003).","journal-title":"Am. J. Surg. Pathol."},{"key":"1164_CR7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","volume":"148","author":"RL James","year":"2024","unstructured":"James, R. L. et al. Development of an FR\u03b1 companion diagnostic immunohistochemical assay for mirvetuximab soravtansine. Arch. Pathol. Lab. Med. 148, 1226\u20131233 (2024).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1164_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann. Oncol. 32, 757\u2013765 (2021).","journal-title":"Ann. Oncol."},{"key":"1164_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436\u20132445 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","volume":"36","author":"A Alvarez Secord","year":"2025","unstructured":"Alvarez Secord, A. et al. The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann. Oncol. 36, 321\u2013330 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","volume":"188","author":"BL Manning-Geist","year":"2024","unstructured":"Manning-Geist, B. L. et al. Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities. Gynecol. Oncol. 188, 52\u201357 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","volume":"191","author":"T Rushton","year":"2024","unstructured":"Rushton, T. et al. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma. Gynecol. Oncol. 191, 80\u201385 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR13","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.ENDO24-B013","volume":"30","author":"RL Porter","year":"2024","unstructured":"Porter, R. L. et al. Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC) [abstract]. Clin. Cancer Res. 30, B013 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/PGP.0000000000001051","volume":"44","author":"S Yazaki","year":"2025","unstructured":"Yazaki, S. et al. Folate receptor alpha expression and the tumor immune microenvironment in patients with cervical cancer. Int. J. Gynecol. Pathol. 44, 104\u2013111 (2025).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1164_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/fon-2017-0379","volume":"14","author":"KN Moore","year":"2018","unstructured":"Moore, K. N. et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 14, 123\u2013136 (2018).","journal-title":"Future Oncol."},{"key":"1164_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore, K. N. et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol. 35, 1112\u20131118 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR17","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389, 2162\u20132174 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1164_CR18","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant (2022)."},{"key":"1164_CR19","unstructured":"US Food and Drug Administration. FDA approves mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian (2024)."},{"key":"1164_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin, L. P. et al. Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody\u2013drug conjugate mirvetuximab soravtansine. Gynecol. Oncol. 147, 402\u2013407 (2017).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","volume":"192","author":"RA Previs","year":"2025","unstructured":"Previs, R. A. et al. Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol. 192, 102\u2013110 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR22","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.3390\/ijms26115222","volume":"26","author":"GF Zannoni","year":"2025","unstructured":"Zannoni, G. F. et al. Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker. Int. J. Mol. Sci. 26,\u00a05222\u00a0(2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1164_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert, L. et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 170, 241\u2013247 (2023).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR24","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","volume":"35","author":"S Pignata","year":"2017","unstructured":"Pignata, S. et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J. Clin. Oncol. 35, 3347\u20133353 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2026.02.026","volume":"208","author":"G Konecny","year":"2026","unstructured":"Konecny, G. et al. Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer [abstract]. Gynecol. Oncol. 208, S454 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-2890","volume":"80","author":"O Ab","year":"2020","unstructured":"Ab, O. et al. IMGN151 \u2014 A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression [abstract]. Cancer Res. 80, 2890 (2020).","journal-title":"Cancer Res."},{"key":"1164_CR27","unstructured":"Sutro Biopharma. Sutro Biopharma announces strategic portfolio review resulting in the prioritization of its next-generation ADC pipeline. Sutro Biopharma https:\/\/ir.sutrobio.com\/press-releases\/detail\/209\/sutro-biopharma-announces-strategic-portfolio-review-resulting-in-the-prioritization-of-its-next-generation-adc-pipeline (2025)."},{"key":"1164_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2007.05.018","volume":"107","author":"JE Allard","year":"2007","unstructured":"Allard, J. E. et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol. Oncol. 107, 52\u201357 (2007).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/PGP.0000000000000736","volume":"40","author":"KZ Hanley","year":"2021","unstructured":"Hanley, K. Z., Horowitz, I. R., Gordon, A., Meisel, J. & Khanna, N. Folate receptor alpha is preferentially expressed in the carcinoma component of endometrial carcinosarcomas: a potential target for adjuvant therapy. Int. J. Gynecol. Pathol. 40, 501\u2013509 (2021).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1164_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1757","volume":"36","author":"N Cloven","year":"2025","unstructured":"Cloven, N. et al. Rinatabart sesutecan (Rina-S\u00ae) for patients with advanced or recurrent endometrial cancer (a\/r EC): update from dose expansion cohort B2 of RAINFOL-01 [abstract 1121P]. Ann. Oncol. 36, S700 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR31","doi-asserted-by":"crossref","unstructured":"Martin, L. et al. Phase I expansion study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in patients with endometrial cancer. Poster presented at European Society of Gynaecological Oncology Congress (Vienna, 2017).","DOI":"10.26226\/morressier.59ba7298d462b80296ca210c"},{"key":"1164_CR32","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1016\/j.annonc.2023.09.1920","volume":"34","author":"B Pothuri","year":"2023","unstructured":"Pothuri, B. et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent\/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion [abstract 741MO]. Ann. Oncol. 34, S508 (2023).","journal-title":"Ann. Oncol."},{"key":"1164_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","volume":"191","author":"KN Moore","year":"2024","unstructured":"Moore, K. N. et al. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary. Gynecol. Oncol. 191, 249\u2013258 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155","volume":"47","author":"A Hendershot","year":"2023","unstructured":"Hendershot, A. et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol. Oncol. Rep. 47, 101155 (2023).","journal-title":"Gynecol. Oncol. Rep."},{"key":"1164_CR35","doi-asserted-by":"publisher","first-page":"102867","DOI":"10.1016\/j.ctrv.2024.102867","volume":"134","author":"B Bouguerra Zina","year":"2025","unstructured":"Bouguerra Zina, B., Rousseau, F., Fauquier, S., Sabatier, R. & Kfoury, M. Practical clinical management of ocular adverse events related to antibody\u2013drug conjugates in gynaecological malignancies. Cancer Treat. Rev. 134,\u00a0102867\u00a0(2025).","journal-title":"Cancer Treat. Rev."},{"key":"1164_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","volume":"26","author":"T Van Gorp","year":"2025","unstructured":"Van Gorp, T. et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 26, 503\u2013515 (2025).","journal-title":"Lancet Oncol."},{"key":"1164_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","volume":"35","author":"DS Ross","year":"2022","unstructured":"Ross, D. S. et al. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. Mod. Pathol. 35, 962\u2013971 (2022).","journal-title":"Mod. Pathol."},{"key":"1164_CR39","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-20-4436","volume":"27","author":"A Momeni-Boroujeni","year":"2021","unstructured":"Momeni-Boroujeni, A. et al. Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin. Cancer Res. 27, 2613\u20132623 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152150","volume":"65","author":"H Yoshida","year":"2023","unstructured":"Yoshida, H. et al. Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: a proposal for HER2-targeted therapy specimen selection. Ann. Diagn. Pathol. 65, 152150 (2023).","journal-title":"Ann. Diagn. Pathol."},{"key":"1164_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101251","volume":"49","author":"E Abada","year":"2023","unstructured":"Abada, E., Singh, K., Hansen, K. & Quddus, M. R. Low-level expression of human epidermal growth factor receptor-2 (HER2) in high-grade mullerian tumors: implications for therapy decision making. Gynecol. Oncol. Rep. 49, 101251 (2023).","journal-title":"Gynecol. Oncol. Rep."},{"key":"1164_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101758","volume":"35","author":"AA Secord","year":"2025","unstructured":"Secord, A. A. et al. Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Int. J. Gynecol. Cancer 35, 101758 (2025).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"1164_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2025.03.011","volume":"195","author":"EK Lee","year":"2025","unstructured":"Lee, E. K., Kolin, D. L., Matulonis, U. A. & Erickson, B. K. Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers. Gynecol. Oncol. 195, 152\u2013164 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR44","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa, T. et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J. Clin. Oncol. 41, 2789\u20132799 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.20517\/cdr.2022.52","volume":"6","author":"S Escriv\u00e1-de-Roman\u00ed","year":"2023","unstructured":"Escriv\u00e1-de-Roman\u00ed, S. & Saura, C. The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody\u2013drug conjugates. Cancer Drug. Resist. 6, 45\u201358 (2023).","journal-title":"Cancer Drug. Resist."},{"key":"1164_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5528","volume":"42","author":"G Yuan","year":"2024","unstructured":"Yuan, G. et al. Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r\/mCC): interim results of RC48-C018 [abstract]. J. Clin. Oncol. 42, 5528 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5564","volume":"43","author":"T Shu","year":"2025","unstructured":"Shu, T. et al. Preliminary analysis of disitamab vedotin combined therapy for HER2-expressing platinum-sensitive recurrent ovarian\/peritoneal\/fallopian tube cancer (Diversity study): a single-arm, multicenter phase II trial [abstract]. J. Clin. Oncol. 43, 5564 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5557","volume":"43","author":"X Wu","year":"2025","unstructured":"Wu, X. et al. JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): updated findings from two clinical trials [abstract]. J. Clin. Oncol. 43, 5557 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR49","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1016\/j.annonc.2025.08.1717","volume":"36","author":"X Wu","year":"2025","unstructured":"Wu, X. et al. Biparatopic anti-HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum-refractory ovarian cancer (OC) [abstract 1079P]. Ann. Oncol. 36, S680 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR50","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ygyno.2026.01.054","volume":"208","author":"B Pothuri","year":"2026","unstructured":"Pothuri, B. et al. Trastuzumab pamirtecan (DB-1303\/BNT323) in patients with previously treated HER2-expressing advanced\/metastatic endometrial cancer: first global clinical phase 2 data [abstract]. Gynecol. Oncol. 208, S32 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR51","unstructured":"Center for Drug Evaluation and Research. Approval Package for: 761139Orig1s028: ENHERTU (fam-trastuzumab deruxtecan-nxki). FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761139Orig1s028.pdf (2024)."},{"key":"1164_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell, C. A. et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 7, 100554 (2022).","journal-title":"ESMO Open."},{"key":"1164_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","volume":"19","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol. Pract. 19, 539\u2013546 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"1164_CR54","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","volume":"36","author":"HS Rugo","year":"2025","unstructured":"Rugo, H. S. et al. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis. Ann. Oncol. 36, 1389\u20131399 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR55","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood.V81.3.734.734","volume":"81","author":"JH Morrissey","year":"1993","unstructured":"Morrissey, J. H., Macik, B. G., Neuenschwander, P. F. & Comp, P. C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81, 734\u2013744 (1993).","journal-title":"Blood"},{"key":"1164_CR56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nm841","volume":"9","author":"VY Bogdanov","year":"2003","unstructured":"Bogdanov, V. Y. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat. Med. 9, 458\u2013462 (2003).","journal-title":"Nat. Med."},{"key":"1164_CR57","first-page":"4075","volume":"16","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. Expression of tissue factor in human cervical carcinoma tissue. Exp. Ther. Med. 16, 4075\u20134081 (2018).","journal-title":"Exp. Ther. Med."},{"key":"1164_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102453","volume":"59","author":"ML Ulvang","year":"2025","unstructured":"Ulvang, M. L. et al. Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions. Transl. Oncol. 59, 102453 (2025).","journal-title":"Transl. Oncol."},{"key":"1164_CR59","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10585-011-9401-0","volume":"28","author":"E Cocco","year":"2011","unstructured":"Cocco, E. et al. Tissue factor expression in ovarian cancer: implications for immunotherapywith hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clin. Exp. Metastasis 28, 689\u2013700 (2011).","journal-title":"Clin. Exp. Metastasis"},{"key":"1164_CR60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/PGP.0b013e3181ff9234","volume":"30","author":"O Fadare","year":"2011","unstructured":"Fadare, O., Renshaw, I. L. & Liang, S. X. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events. Int. J. Gynecol. Pathol. 30, 252\u2013261 (2011).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1164_CR61","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/sj.bjc.6605760","volume":"103","author":"E Cocco","year":"2010","unstructured":"Cocco, E. et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br. J. Cancer 103, 812\u2013819 (2010).","journal-title":"Br. J. Cancer"},{"key":"1164_CR62","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","volume":"74","author":"EC Breij","year":"2014","unstructured":"Breij, E. C. et al. An antibody\u2013drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 74, 1214\u20131226 (2014).","journal-title":"Cancer Res."},{"key":"1164_CR63","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono, J. S. et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 20, 383\u2013393 (2019).","journal-title":"Lancet Oncol."},{"key":"1164_CR64","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","volume":"26","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin. Cancer Res. 26, 1220\u20131228 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR65","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman, R. L. et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 609\u2013619 (2021).","journal-title":"Lancet Oncol."},{"key":"1164_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote, I. et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N. Engl. J. Med. 391, 44\u201355 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1164_CR67","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 Study. J. Clin. Oncol. 41, 5536\u20135549 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5602","volume":"37","author":"H Mahdi","year":"2019","unstructured":"Mahdi, H. et al. Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) [abstract]. J. Clin. Oncol. 37, TPS5602 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR69","unstructured":"US Food and Drug Administration. Prescribing information: TIVDAK (tisotumab vedotin-tftv) for injection, for intravenous use. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761208s010lbl.pdf (2025)."},{"key":"1164_CR70","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","volume":"78","author":"M Lipinski","year":"1981","unstructured":"Lipinski, M., Parks, D. R., Rouse, R. V. & Herzenberg, L. A. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl Acad. Sci. USA 78, 5147\u20135150 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1164_CR71","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum, D. et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology 89, 245\u2013258 (2022).","journal-title":"Pathobiology"},{"key":"1164_CR72","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","volume":"46","author":"E Bignotti","year":"2010","unstructured":"Bignotti, E. et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur. J. Cancer 46, 944\u2013953 (2010).","journal-title":"Eur. J. Cancer"},{"key":"1164_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6890-12-22","volume":"12","author":"E Bignotti","year":"2012","unstructured":"Bignotti, E. et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin. Pathol. 12, 22 (2012).","journal-title":"BMC Clin. Pathol."},{"key":"1164_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075864","volume":"8","author":"T Liu","year":"2013","unstructured":"Liu, T. et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS ONE 8, e75864 (2013).","journal-title":"PLoS ONE"},{"key":"1164_CR75","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","volume":"35","author":"A Oaknin","year":"2024","unstructured":"Oaknin, A. et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study [abstract 714MO]. Ann. Oncol. 35, S547\u2013S548 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR76","first-page":"S548","volume":"35","author":"D Wang","year":"2024","unstructured":"Wang, D. et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study [abstract 715MO]. Ann. Oncol. 35, S548 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2025.03.061","volume":"200","author":"M Rubinstein","year":"2025","unstructured":"Rubinstein, M. et al. DB-1305\/BNT325, a novel trophoblast cell-surface antigen 2 antibody\u2013drug conjugate, in patients with ovarian cancer: efficacy and safety data from a phase I\/II study. Gynecol. Oncol. 200, 9\u201310 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR78","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/j.annonc.2024.08.779","volume":"35","author":"Z Song","year":"2024","unstructured":"Song, Z. et al. SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study [absract 717MO]. Ann. Oncol. 35, S549 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR79","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","volume":"42","author":"AD Santin","year":"2024","unstructured":"Santin, A. D. et al. Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. J. Clin. Oncol. 42, 3421\u20133429 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR80","doi-asserted-by":"publisher","first-page":"S693","DOI":"10.1016\/j.annonc.2025.08.1748","volume":"36","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. Sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic endometrial carcinoma: results from a phase 1\/2 study (2870-001\/KL264-01) [abstract 1111P]. Ann. Oncol. 36, S693\u2013S694 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR81","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ygyno.2024.07.038","volume":"190","author":"J An","year":"2024","unstructured":"An, J. et al. Sacituzumab govitecan for Chinese patients with recurrent\/metastatic cervical cancer: interim analysis of the phase II basket study EVER-132-003 [abstract]. Gynecol. Oncol. 190, S22 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR82","first-page":"S548","volume":"35","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer [abstract 716MO]. Ann. Oncol. 35, S548\u2013S549 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR83","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.ygyno.2026.01.080","volume":"208","author":"X Wu","year":"2026","unstructured":"Wu, X. et al. Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab in participants with recurrent or metastatic cervical cancer: results from the phase 22870-002\/SKB264-II-06 study [abstract]. Gynecol. Oncol. 208, S36\u2013S37 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR84","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.ygyno.2026.01.781","volume":"208","author":"Q Xu","year":"2026","unstructured":"Xu, Q. et al. A multicenter, open-label, phase I\/II study of IBI130, a TROP2-targeting antibody\u2013drug conjugate, as monotherapy in patients with recurrent or metastatic cervical cancer [abstract]. Gynecol. Oncol. 208, S67 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J. Histochem. Cytochem. 59, 701\u2013710 (2011).","journal-title":"J. Histochem. Cytochem."},{"key":"1164_CR86","first-page":"oyaf031","volume":"30","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam, F. et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis. Oncologist 30,\u00a0oyaf031\u00a0(2025).","journal-title":"Oncologist"},{"key":"1164_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/dbio.1996.8501","volume":"183","author":"T Inoue","year":"1997","unstructured":"Inoue, T., Chisaka, O., Matsunami, H. & Takeichi, M. Cadherin-6 expression transiently delineates specific rhombomeres, other neural tube subdivisions, and neural crest subpopulations in mouse embryos. Dev. Biol. 183, 183\u2013194 (1997).","journal-title":"Dev. Biol."},{"key":"1164_CR88","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2011.07.006","volume":"71","author":"JA Osterhout","year":"2011","unstructured":"Osterhout, J. A. et al. Cadherin-6 mediates axon-target matching in a non-image-forming visual circuit. Neuron 71, 632\u2013639 (2011).","journal-title":"Neuron"},{"key":"1164_CR89","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1242\/dev.125.5.803","volume":"125","author":"EA Cho","year":"1998","unstructured":"Cho, E. A. et al. Differential expression and function of cadherin-6 during renal epithelium development. Development 125, 803\u2013812 (1998).","journal-title":"Development"},{"key":"1164_CR90","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.annonc.2023.09.1955","volume":"34","author":"D Shintani","year":"2023","unstructured":"Shintani, D. et al. Targeting cadherin-6 in epithelial ovarian cancer: clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models [abstract 777P]. Ann. Oncol. 34, S525\u2013S526 (2023).","journal-title":"Ann. Oncol."},{"key":"1164_CR91","doi-asserted-by":"publisher","first-page":"S1585","DOI":"10.1016\/j.annonc.2025.09.054","volume":"36","author":"IL Ray-Coquard","year":"2025","unstructured":"Ray-Coquard, I. L. et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01 [abstract LBA42]. Ann. Oncol. 36, S1585\u2013S1586 (2025).","journal-title":"Ann. Oncol."},{"key":"1164_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","volume":"23","author":"H Suzuki","year":"2024","unstructured":"Suzuki, H. et al. Raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models. Mol. Cancer Ther. 23, 257\u2013271 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1164_CR93","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-16-1414","volume":"7","author":"CU Bialucha","year":"2017","unstructured":"Bialucha, C. U. et al. Discovery and optimization of HKT288, a cadherin-6\u2013targeting ADC for the treatment of ovarian and renal cancers. Cancer Discov. 7, 1030\u20131045 (2017).","journal-title":"Cancer Discov."},{"key":"1164_CR94","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1159\/000518549","volume":"44","author":"P Sch\u00f6ffski","year":"2021","unstructured":"Sch\u00f6ffski, P. et al. A phase 1 study of a CDH6-targeting antibody-drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncol. Res. Treat. 44, 547\u2013556 (2021).","journal-title":"Oncol. Res. Treat."},{"key":"1164_CR95","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.ygyno.2024.07.017","volume":"190","author":"K Moore","year":"2024","unstructured":"Moore, K. et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: subgroup analysis of a first-in-human phase I study [abstract LBA04]. Gynecol. Oncol. 190, S6\u2013S7 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR96","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6320","volume":"83","author":"W Lu","year":"2023","unstructured":"Lu, W. et al. CUSP06\/AMT-707, a new CDH6-targeting antibody-drug conjugate, demonstrates potent antitumor activity in preclinical models [abstract]. Cancer Res. 83, 6320 (2023).","journal-title":"Cancer Res."},{"key":"1164_CR97","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2026-CT037","volume":"86","author":"Y Xiang","year":"2026","unstructured":"Xiang, Y. et al. A phase 1, first in human study of QLS5132, a novel claudin 6 (CLDN6)-targeting antibody drug (ADC) conjugate in patients (pts) with platinum resistant ovarian cancer [abstract]. Cancer Res. 86, CT037 (2026).","journal-title":"Cancer Res."},{"key":"1164_CR98","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","volume":"18","author":"GL Sica","year":"2003","unstructured":"Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849\u2013861 (2003).","journal-title":"Immunity"},{"key":"1164_CR99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3892\/or.2016.4807","volume":"36","author":"X Zhao","year":"2016","unstructured":"Zhao, X. et al. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma. Oncol. Rep. 36, 419\u2013427 (2016).","journal-title":"Oncol. Rep."},{"key":"1164_CR100","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","volume":"67","author":"I Kryczek","year":"2007","unstructured":"Kryczek, I. et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900\u20138905 (2007).","journal-title":"Cancer Res."},{"key":"1164_CR101","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.yexcr.2018.08.014","volume":"371","author":"S Han","year":"2018","unstructured":"Han, S. et al. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer. Exp. Cell Res. 371, 222\u2013230 (2018).","journal-title":"Exp. Cell Res."},{"key":"1164_CR102","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41379-021-00979-4","volume":"35","author":"L Zong","year":"2022","unstructured":"Zong, L. et al. Expression of B7 family checkpoint proteins in cervical cancer. Mod. Pathol. 35, 786\u2013793 (2022).","journal-title":"Mod. Pathol."},{"key":"1164_CR103","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2017.03.006","volume":"145","author":"A Bregar","year":"2017","unstructured":"Bregar, A. et al. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol. Oncol. 145, 446\u2013452 (2017).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR104","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-1765","volume":"82","author":"K Kinneer","year":"2022","unstructured":"Kinneer, K. et al. Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead [abstract]. Cancer Res. 82, 1765 (2022).","journal-title":"Cancer Res."},{"key":"1164_CR105","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871\u2013881 (2006).","journal-title":"J. Exp. Med."},{"key":"1164_CR106","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2005.08.060","volume":"100","author":"B Tringler","year":"2006","unstructured":"Tringler, B. et al. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 100, 44\u201352 (2006).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR107","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.4049\/jimmunol.171.9.4650","volume":"171","author":"IH Choi","year":"2003","unstructured":"Choi, I. H. et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650\u20134654 (2003).","journal-title":"J. Immunol."},{"key":"1164_CR108","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1038\/onc.2012.600","volume":"32","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 32, 5347\u20135358 (2013).","journal-title":"Oncogene"},{"key":"1164_CR109","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-04-3550","volume":"66","author":"I Simon","year":"2006","unstructured":"Simon, I. et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66, 1570\u20131575 (2006).","journal-title":"Cancer Res."},{"key":"1164_CR110","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ygyno.2007.03.007","volume":"106","author":"I Simon","year":"2007","unstructured":"Simon, I. et al. Evaluation of the novel serum markers B7-H4, spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 106, 112\u2013118 (2007).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR111","doi-asserted-by":"publisher","first-page":"S464","DOI":"10.1016\/j.annonc.2023.09.1846","volume":"34","author":"CA Perez","year":"2023","unstructured":"Perez, C. A. et al. First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase I study (SGNB7H4V-001) [abstract 660MO]. Ann. Oncol. 34, S464\u2013S465 (2023).","journal-title":"Ann. Oncol."},{"key":"1164_CR112","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ygyno.2025.04.502","volume":"200","author":"S Gaillard","year":"2025","unstructured":"Gaillard, S. et al. Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: a first-in-human phase I\/IIa study [abstract]. Gynecol. Oncol. 200, 347\u2013348 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3009","volume":"43","author":"EP Hamilton","year":"2025","unstructured":"Hamilton, E. P. et al. Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate [abstract]. J. Clin. Oncol. 43, 3009 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR114","doi-asserted-by":"publisher","first-page":"S454","DOI":"10.1016\/j.ygyno.2026.02.027","volume":"208","author":"A Oaknin","year":"2026","unstructured":"Oaknin, A. et al. Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): first results from the global BEHOLD-1 study [abstract]. Gynecol. Oncol. 208, S454\u2013S455 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413416","volume":"22","author":"H Qu","year":"2021","unstructured":"Qu, H., Jin, Q. & Quan, C. CLDN6: from traditional barrier function to emerging roles in cancers. Int. J. Mol. Sci. 22, 13416 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1164_CR116","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","volume":"29","author":"MSJ McDermott","year":"2023","unstructured":"McDermott, M. S. J. et al. Preclinical efficacy of the antibody\u2013drug conjugate CLDN6\u201323-ADC for the treatment of CLDN6-positive solid tumors. Clin. Cancer Res. 29, 2131\u20132143 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR117","doi-asserted-by":"publisher","first-page":"S385","DOI":"10.1016\/j.ygyno.2026.01.664","volume":"208","author":"J Silverstein","year":"2026","unstructured":"Silverstein, J. et al. Claudin-6 expression in ovarian cancer and its associations with other clinically relevant biomarkers [abstract]. Gynecol. Oncol. 208, S385 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR118","doi-asserted-by":"publisher","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.783","volume":"35","author":"GE Konecny","year":"2024","unstructured":"Konecny, G. E. et al. Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors [abstract 721MO]. Ann. Oncol. 35, S551 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR119","doi-asserted-by":"publisher","first-page":"S488","DOI":"10.1016\/j.annonc.2024.08.677","volume":"35","author":"MR Patel","year":"2024","unstructured":"Patel, M. R. et al. Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6 [abstract 610O]. Ann. Oncol. 35, S488\u2013S489 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR120","doi-asserted-by":"publisher","first-page":"102489","DOI":"10.1016\/j.ctrv.2022.102489","volume":"112","author":"S Banerjee","year":"2023","unstructured":"Banerjee, S., Drapkin, R., Richardson, D. L. & Birrer, M. Targeting NaPi2b in ovarian cancer. Cancer Treat. Rev. 112,\u00a0102489\u00a0(2023).","journal-title":"Cancer Treat. Rev."},{"key":"1164_CR121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8660","volume":"43","author":"T Van Gorp","year":"2025","unstructured":"Van Gorp, T. et al. NAPISTAR 1-01: an international phase I\/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 43, TPS8660 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR122","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-1894","volume":"84","author":"L Xiao","year":"2024","unstructured":"Xiao, L. et al. Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors [abstract]. Cancer Res. 84, 1894 (2024).","journal-title":"Cancer Res."},{"key":"1164_CR123","doi-asserted-by":"publisher","first-page":"S1586","DOI":"10.1016\/j.annonc.2025.09.055","volume":"36","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2025","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. NAPISTAR 1-01: a phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC) [abstract LBA43]. Ann. Oncol. 36, S1586\u2013S1587 (2025) .","journal-title":"Ann. Oncol."},{"key":"1164_CR124","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda, E., Ohaegbulam, K. C. & Zang, X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin. Cancer Res. 22, 3425\u20133431 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR125","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.ygyno.2026.01.057","volume":"208","author":"J Zuo","year":"2026","unstructured":"Zuo, J., Xin, Y., Shi, S. & Wu, L. SYS6043, a B7-H3 targeting antibody-drug conjugates in patients with advanced gynecologic cancers: a phase 1\/2, first-in-human study [abstract]. Gynecol. Oncol. 208, S34 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR126","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ygyno.2026.01.022","volume":"208","author":"I Winer","year":"2026","unstructured":"Winer, I. et al. A global, phase 1\/2 study of DB-1311\/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: outcomes by prior treatment [abstract]. Gynecol. Oncol. 208, S22\u2013S23 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR127","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2884","volume":"85","author":"M Xu","year":"2025","unstructured":"Xu, M., Rueda, B., Spriggs, D. & Oladapo, Y. Development of antibody drug conjugates targeting MUC16 in ovarian cancer subtypes [abstract]. Cancer Res. 85, 2884 (2025).","journal-title":"Cancer Res."},{"key":"1164_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223703","volume":"17","author":"A Scheiter","year":"2025","unstructured":"Scheiter, A. et al. Results of the first folate receptor alpha testing trial by the german quality assurance initiative in pathology (QuIP\u00ae). Cancers 17, 3703 (2025).","journal-title":"Cancers"},{"key":"1164_CR129","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/PAI.0000000000000930","volume":"29","author":"H Lara","year":"2021","unstructured":"Lara, H. et al. Quantitative image analysis for tissue biomarker use: a white paper from the Digital Pathology Association. Appl. Immunohistochem. Mol. Morphol. 29, 479\u2013493 (2021).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"1164_CR130","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5858\/arpa.2018-0378-CP","volume":"143","author":"MM Bui","year":"2019","unstructured":"Bui, M. M. et al. Quantitative image analysis of human epidermal growth factor receptor 2 immunohistochemistry for breast cancer: guideline from the College of American Pathologists. Arch. Pathol. Lab. Med. 143, 1180\u20131195 (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1164_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102070","volume":"104","author":"BS Knudsen","year":"2024","unstructured":"Knudsen, B. S. et al. A pipeline for evaluation of machine learning\/artificial intelligence models to quantify programmed death ligand 1 immunohistochemistry. Lab. Invest. 104, 102070 (2024).","journal-title":"Lab. Invest."},{"key":"1164_CR132","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41591-024-02857-3","volume":"30","author":"RJ Chen","year":"2024","unstructured":"Chen, R. J. et al. Towards a general-purpose foundation model for computational pathology. Nat. Med. 30, 850\u2013862 (2024).","journal-title":"Nat. Med."},{"key":"1164_CR133","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/cells14161282","volume":"14","author":"VM Ettorre","year":"2025","unstructured":"Ettorre, V. M., Palmieri, L., Clemente, V. & Santin, A. D. HER2\/neu as a signaling and therapeutic marker in uterine serous carcinoma. Cells 14, 1282 (2025).","journal-title":"Cells"},{"key":"1164_CR134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/PGP.0000000000001140","volume":"45","author":"B Liang","year":"2025","unstructured":"Liang, B. et al. Heterogeneity and scoring reproducibility of folate receptor 1 immunohistochemistry in high-grade serous carcinoma. Int. J. Gynecol. Pathol. 45, 9\u201317 (2025).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1164_CR135","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/PGP.0000000000001053","volume":"44","author":"BC Lawson","year":"2025","unstructured":"Lawson, B. C., Marques-Piubelli, M. L., Westin, S. N. & Malpica, A. Folate receptor immunohistochemical staining and gynecologic tumors: initial experience with 216 cases. Int. J. Gynecol. Pathol. 44, 167\u2013173 (2025).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1164_CR136","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/modpathol.2012.59","volume":"25","author":"IZ Yildiz-Aktas","year":"2012","unstructured":"Yildiz-Aktas, I. Z., Dabbs, D. J. & Bhargava, R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod. Pathol. 25, 1098\u20131105 (2012).","journal-title":"Mod. Pathol."},{"key":"1164_CR137","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00428-019-02595-9","volume":"475","author":"M van Seijen","year":"2019","unstructured":"van Seijen, M. et al. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch. 475, 191\u2013199 (2019).","journal-title":"Virchows Arch."},{"key":"1164_CR138","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00428-020-02848-y","volume":"478","author":"T Radonic","year":"2021","unstructured":"Radonic, T. et al. Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. Virchows Arch. 478, 293\u2013300 (2021).","journal-title":"Virchows Arch."},{"key":"1164_CR139","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1369\/0022155421995600","volume":"69","author":"A Bagchi","year":"2021","unstructured":"Bagchi, A. et al. Impact of preanalytical factors on the measurement of tumor tissue biomarkers using immunohistochemistry. J. Histochem. Cytochem. 69, 297\u2013320 (2021).","journal-title":"J. Histochem. Cytochem."},{"key":"1164_CR140","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00428-020-02960-z","volume":"478","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols. Virchows Arch. 478, 985\u2013993 (2021).","journal-title":"Virchows Arch."},{"key":"1164_CR141","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PAI.0000000000000730","volume":"28","author":"R Miller","year":"2020","unstructured":"Miller, R. et al. Impact of pre-analytical conditions on the antigenicity of lung markers: ALK and MET. Appl. Immunohistochem. Mol. Morphol. 28, 331\u2013338 (2020).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"1164_CR142","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208\u20132215 (2024).","journal-title":"Nat. Med."},{"key":"1164_CR143","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang, H. L., Schwettmann, B., McArthur, H. L. & Chan, I. S. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J. Clin. Invest. 133,\u00a0e172156\u00a0(2023).","journal-title":"J. Clin. Invest."},{"key":"1164_CR144","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.3390\/cancers14163996","volume":"14","author":"I Schlam","year":"2022","unstructured":"Schlam, I., Tarantino, P. & Tolaney, S. M. Overcoming resistance to HER2-directed therapies in breast cancer. Cancers 14,\u00a03996\u00a0(2022).","journal-title":"Cancers"},{"key":"1164_CR145","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen, R. et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol. Cancer Ther. 14, 1376\u20131384 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1164_CR146","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cub.2006.04.043","volume":"16","author":"DA Brito","year":"2006","unstructured":"Brito, D. A. & Rieder, C. L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16, 1194\u20131200 (2006).","journal-title":"Curr. Biol."},{"key":"1164_CR147","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1164_CR148","doi-asserted-by":"publisher","first-page":"S550","DOI":"10.1016\/j.annonc.2024.08.781","volume":"35","author":"EK Lee","year":"2024","unstructured":"Lee, E. K. et al. A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer [abstract 719MO]. Ann. Oncol. 35, S550 (2024).","journal-title":"Ann. Oncol."},{"key":"1164_CR149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","volume":"41","author":"RO Abelman","year":"2023","unstructured":"Abelman, R. O. et al. Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study [abstract]. J. Clin. Oncol. 41, 1022 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.047","volume":"200","author":"W Manning","year":"2025","unstructured":"Manning, W. et al. Mechanisms of resistance to anti-MUC16\/MMAE antibody\u2013drug conjugate therapy in ovarian cancer [abstract]. Gynecol. Oncol. 200, 67 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101158","volume":"64","author":"S Sato","year":"2025","unstructured":"Sato, S. et al. Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. Neoplasia 64, 101158 (2025).","journal-title":"Neoplasia"},{"key":"1164_CR152","doi-asserted-by":"publisher","first-page":"105200","DOI":"10.1016\/j.esmoop.2025.105200","volume":"10","author":"K Hamagawa","year":"2025","unstructured":"Hamagawa, K. et al. Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): opportunities for targeted treatment strategies [abstract 71O]. ESMO Open\u00a010 (suppl. 5), 105200\u00a0(2025).","journal-title":"ESMO Open"},{"key":"1164_CR153","doi-asserted-by":"publisher","first-page":"S707","DOI":"10.1016\/j.annonc.2025.08.1771","volume":"36","author":"M Fukuda","year":"2025","unstructured":"Fukuda, M. et al. Differential expression of key therapeutic target proteins across ovarian cancer histologic subtypes [abstract 1135P]. Ann. Oncol. 36, S707\u2013S708 (2025) .","journal-title":"Ann. Oncol."},{"key":"1164_CR154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5591","volume":"43","author":"EM Swisher","year":"2025","unstructured":"Swisher, E. M. et al. Folate receptor alpha (FR\u03b1; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort [abstract]. J. Clin. Oncol. 43, 5591 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR155","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ygyno.2025.10.029","volume":"203","author":"J Park","year":"2025","unstructured":"Park, J. et al. Prognostic implications of HER2 in ovarian cancer: associations with homologous recombination deficiency and folate receptor alpha expression. Gynecol. Oncol. 203, 151\u2013157 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR156","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789\u2013802 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"1164_CR157","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"1164_CR158","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Liu, K., Wang, K. & Zhu, H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer 129, 283\u2013295 (2023).","journal-title":"Cancer"},{"key":"1164_CR159","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/j.annonc.2020.08.975","volume":"31","author":"EP Hamilton","year":"2020","unstructured":"Hamilton, E. P. et al. Safety and efficacy of XMT-1536 in ovarian cancer: a subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate [abstract 836P]. Ann. Oncol. 31, S627\u2013S628 (2020).","journal-title":"Ann. Oncol."},{"key":"1164_CR160","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.ygyno.2024.07.085","volume":"190","author":"D Richardson","year":"2024","unstructured":"Richardson, D. et al. UPLIFT (ENGOT-OV67\/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer [abstract LBA13]. Gynecol. Oncol. 190, S56 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR161","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","volume":"27","author":"T Shimizu","year":"2021","unstructured":"Shimizu, T. et al. First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors. Clin. Cancer Res. 27, 3905\u20133915 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5513","volume":"40","author":"S Nishio","year":"2022","unstructured":"Nishio, S. et al. Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): results from the expansion part of a phase 1 trial [abstract]. J. Clin. Oncol. 40, 5513 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR163","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","volume":"41","author":"A Oaknin","year":"2023","unstructured":"Oaknin, A. et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolR\u03b1 expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort [abstract]. J. Clin. Oncol. 41, 5508 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR164","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ygyno.2025.04.507","volume":"200","author":"JY Lee","year":"2025","unstructured":"Lee, J. Y. et al. Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: results from the dose-optimization stage of the REFR\u03b1ME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II\/III study [abstract]. Gynecol. Oncol. 200, 351 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR165","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen, T. D., Bordeau, B. M. & Balthasar, J. P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 15,\u00a0713\u00a0(2023).","journal-title":"Cancers"},{"key":"1164_CR166","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/abt\/tbaf004","volume":"8","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y. et al. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antib. Therapeutics 8, 124\u2013144 (2025).","journal-title":"Antib. Therapeutics"},{"key":"1164_CR167","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cpt.2278","volume":"110","author":"MZ Liao","year":"2021","unstructured":"Liao, M. Z. et al. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US food and drug administration-approved antibody-drug conjugates? Clin. Pharmacol. Ther. 110, 1216\u20131230 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1164_CR168","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt, K. & Ullrich, A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473\u2013480 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1164_CR169","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ygyno.2023.12.017","volume":"182","author":"MC Cristea","year":"2024","unstructured":"Cristea, M. C. et al. A phase I study of mirvetuximab soravtansine and gemcitabine in patients with fralpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol. Oncol. 182, 124\u2013131 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR170","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.5553","volume":"35","author":"DM O\u2019Malley","year":"2017","unstructured":"O\u2019Malley, D. M. et al. Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer [abstract]. J. Clin. Oncol. 35, 5553 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR171","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","volume":"200","author":"UA Matulonis","year":"2025","unstructured":"Matulonis, U. A. et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 200, 96\u2013104 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5504","volume":"39","author":"DM O\u2019Malley","year":"2021","unstructured":"O\u2019Malley, D. M. et al. Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis [abstract]. J. Clin. Oncol. 39, 5504 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR173","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","volume":"185","author":"DL Richardson","year":"2024","unstructured":"Richardson, D. L. et al. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol. Oncol. 185, 186\u2013193 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR174","doi-asserted-by":"publisher","first-page":"S568","DOI":"10.1016\/j.annonc.2024.08.810","volume":"35","author":"LP Martin","year":"2024","unstructured":"Martin, L. P. et al. Luveltamab tazevibulin, an antifolate receptor alpha (FR\u03b1) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study [abstract 749P]. Ann. Oncol. 35, S568\u2013S569 (2024) .","journal-title":"Ann. Oncol."},{"key":"1164_CR175","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1016\/j.annonc.2025.08.1718","volume":"36","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Efficacy of disitamab vedotin, AK104, and bevacizumab in HER2-positive recurrent ovarian clear cell cancer: Phase II DAB-OCCC trial [abstract 1080P]. Ann. Oncol. 36, S680\u2013S681 (2025) .","journal-title":"Ann. Oncol."},{"key":"1164_CR176","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","volume":"31","author":"HA Alqaisi","year":"2025","unstructured":"Alqaisi, H. A. et al. Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI Trial). Clin. Cancer Res. 31, 993\u20131001 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR177","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.ygyno.2026.01.091","volume":"208","author":"T Van Gorp","year":"2026","unstructured":"Van Gorp, T. et al. Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8\/GOG-3024\/innovaTV 205 study [abstract]. Gynecol. Oncol. 208, S37\u2013S38 (2026).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR178","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-648","volume":"85","author":"EP Hamilton","year":"2025","unstructured":"Hamilton, E. P. et al. Activity of BNT327\/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325\/DB-1305 (TROP2 ADC) in solid tumors: early preclinical and clinical evidence to support BNT327 + ADC combinations [abstract]. Cancer Res. 85, 648 (2025).","journal-title":"Cancer Res."},{"key":"1164_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101988","volume":"35","author":"VM Ettorre","year":"2025","unstructured":"Ettorre, V. M. et al. Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models. Int. J. Gynecol. Cancer 35, 101988 (2025).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"1164_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105046","volume":"218","author":"GF Zannoni","year":"2026","unstructured":"Zannoni, G. F. et al. HER2 in gynecological malignancies: bridging the gap between standardized pathological assessment and precision therapy. Crit. Rev. Oncol. Hematol. 218, 105046 (2026).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1164_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115522","volume":"224","author":"JM Porter","year":"2025","unstructured":"Porter, J. M. et al. Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer. Eur. J. Cancer 224, 115522 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1164_CR182","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1080\/14796694.2025.2561539","volume":"21","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. Future Oncol. 21, 3283\u20133292 (2025).","journal-title":"Future Oncol."},{"key":"1164_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274140","volume":"17","author":"K Inaki","year":"2022","unstructured":"Inaki, K. et al. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis. PLoS ONE 17, e0274140 (2022).","journal-title":"PLoS ONE"},{"key":"1164_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02844-z","volume":"23","author":"Y Kojima","year":"2023","unstructured":"Kojima, Y. et al. Changes in HER3 expression profiles between primary and recurrent gynecological cancers. Cancer Cell Int. 23, 18 (2023).","journal-title":"Cancer Cell Int."},{"key":"1164_CR185","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/biomedicines9040397","volume":"9","author":"S Weidemann","year":"2021","unstructured":"Weidemann, S. et al. Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines\u00a09, 397\u00a0(2021).","journal-title":"Biomedicines"},{"key":"1164_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3289-2","volume":"17","author":"K Levan","year":"2017","unstructured":"Levan, K. et al. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer 17, 303 (2017).","journal-title":"BMC Cancer"},{"key":"1164_CR187","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/his.15533","volume":"88","author":"A McHenry","year":"2025","unstructured":"McHenry, A. et al. Folate receptor alpha (FR\u03b1\/FOLR1) and HER2 immunohistochemical staining in high-grade endometrial carcinoma with aberrant p53 expression. Histopathology 88,\u00a0429\u2013441\u00a0(2025).","journal-title":"Histopathology"},{"key":"1164_CR188","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ygyno.2025.05.001","volume":"197","author":"Y Xiao","year":"2025","unstructured":"Xiao, Y. et al. FR\u03b1 expression in advanced endometrial carcinoma: clinicopathological, molecular, and prognosis correlates. Gynecol. Oncol. 197, 146\u2013154 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1164_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101951","volume":"61","author":"SY Lin","year":"2025","unstructured":"Lin, S. Y., Chang, C. T., Wu, R. C., Lai, C. R. & Chen, Y. J. Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma. Gynecol. Oncol. Rep. 61, 101951 (2025).","journal-title":"Gynecol. Oncol. Rep."},{"key":"1164_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58009-3","volume":"10","author":"B Zeybek","year":"2020","unstructured":"Zeybek, B. et al. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody\u2013drug conjugate sacituzumab govitecan. Sci. Rep. 10, 973 (2020).","journal-title":"Sci. Rep."},{"key":"1164_CR191","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257976","volume":"16","author":"B Itkin","year":"2021","unstructured":"Itkin, B. et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS ONE 16, e0257976 (2021).","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1038\/s41571-026-01208-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01164-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01164-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01164-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:05:07Z","timestamp":1789646707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01164-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":191,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01164-9","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"18 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-026-01208-0","URL":"https:\/\/doi.org\/10.1038\/s41571-026-01208-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.N.M. is a scientific advisory board member and\/or consultant for Aadi, Abbvie, AstraZeneca, BioNTech, BeOne, Corcept, Caris, Daiichi-Sankyo, Genmab, GSK, Immatics, Immunocore, Immunogen, Incyte, Janssen, Merck, Regeneron, Schrodinger, Takeda, Tubulis, Verastem, Whitehawk, Zentalis and Zymeworks; has developed educational content and\/or been a speaker for Oncology Learning Network, Physicians Education Resource, PRIME and Research to Practice; and has had leadership roles with ASCO (board of directors and treasurer), GOG Foundation (board of directors), GOG Partners (Associate Director) and NRG (Ovarian Committee Chair). O.O.Y. works in an institution that receives funding from Ascendis Pharma, BioNTech, Compugen, Gilead, Immatics, Immunocore, Merck, ProfoundBio, Regeneron, Third Arc Bio and TORL Biotherapeutics; has received grant funding from the Department of War and Robert Wood Johnson Foundation; had been an advisory board member for Compugen, Gilead and Immatics; and has had leadership roles with NRG Oncology (Early Phase Trial Oversight Committee Vice-Chair). B.E.H. has received research support from Cartography, Immunogen, Link Cell Sciences and Santa Ana Bio; and has been a paid consultant for Abbvie, Leica, Roche and Tempus, and Abbvie. H.Y. has been a consultant for Affyimmune, Aktis, Ambrx, Arena Bio, Beam, Bicycle Therapeutics, C4 Therapeutics, Cothera Bio, Kymera, Mekanistic, Mersana, Ona Therapeutics, OnCusp Therapeutics, Solid Therapeutics, Treos Bio and Verastem. J.F.L. works in an institution that receives funding from Aravive, AstraZeneca, Biothera Solutions, Bristol Myers Squibb, Daiichi-Sankyo, Genmab, GSK, Impact Therapeutics, NextCure, NiKang, Pheon, Pfizer, Regeneron, Seagen, SystImmune, Volastra and Zentalis Pharmaceuticals; has been a paid consultant for AbbVie and Bristol Myers Squibb; has been an advisory board member for AbbVie, AstraZeneca, Corcept, Daiichi-Sankyo, Genmab, GSK, Loxo Lilly, Merck, PMV, Regeneron, Revolution Medicines, SystImmune and Zentalis Pharmaceuticals; and had leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid, from NCCN (Ovarian Committee Chair), NRG Oncology (Ovarian Subcommittee Vice-Chair) and Tina\u2019s Wish (former Scientific Advisory Board co-chair).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}